Cargando…

Gene Expression Profiling in Hereditary, BRCA1-linked Breast Cancer: Preliminary Report

Global analysis of gene expression by DNA microarrays is nowadays a widely used tool, especially relevant for cancer research. It helps the understanding of complex biology of cancer tissue, allows identification of novel molecular markers, reveals previously unknown molecular subtypes of cancer tha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dudaladava, Volha, Jarząb, Michał, Stobiecka, Ewa, Chmielik, Ewa, Simek, Krzysztof, Huzarski, Tomasz, Lubiński, Jan, Pamuła, Jolanta, Pękala, Wioletta, Grzybowska, Ewa, Lisowska, Katarzyna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401917/ https://www.ncbi.nlm.nih.gov/pubmed/20223001 http://dx.doi.org/10.1186/1897-4287-4-1-28

Ejemplares similares

Gene expression signature of hereditary breast cancer
por: Dudaladava, V, et al.
Publicado: (2005)

Gene Expression Analysis in Ovarian Cancer – Faults and Hints from DNA Microarray Study
por: Lisowska, Katarzyna Marta, et al.
Publicado: (2014)

Functional Impact of Sequence Alterations Found in BRCA1 Promoter/5'UTR Region in Breast/Ovarian Cancer Families from Upper Silesia, Poland
por: Pamuła, Jolanta, et al.
Publicado: (2006)

Prognostic value of lymph node metastases of differentiated thyroid cancer (DTC) according to the local advancement and range of surgical excision
por: Czarniecka, Agnieszka, et al.
Publicado: (2010)

High-throughput genotyping of a common deletion polymorphism disrupting the TRY6 gene and its association with breast cancer risk
por: Wagner, Kerstin, et al.
Publicado: (2007)

Comparison of the expression profile in breast cancer and ovarian cancer
por: Jarzab, M, et al.
Publicado: (2005)

Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma – Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015
por: Czarniecka, Agnieszka, et al.
Publicado: (2021)

Prevalence of the most frequent BRCA1 mutations in Polish population
por: Brozek, Izabela, et al.
Publicado: (2011)

The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAF(V600E) Mutation Status and Other Prognostic Factors
por: Czarniecka, Agnieszka, et al.
Publicado: (2015)

Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours
por: Wojtas, Bartosz, et al.
Publicado: (2017)

Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?
por: Rusinek, Dagmara, et al.
Publicado: (2017)

Analytical sensitivity of a method is critical in detection of low-level BRCA1 constitutional epimutation
por: Machaj, Filip, et al.
Publicado: (2023)

Spectrum of tumors in the families with Hereditary Breast Ovarian Cancer syndrome carrying germline mutations in BRCA1 and 2 genes
por: Budryk, M, et al.
Publicado: (2012)

Publisher Correction: Analytical sensitivity of a method is critical in detection of low-level BRCA1 constitutional epimutation
por: Machaj, Filip, et al.
Publicado: (2023)

Identification of novel sequence alterations and the functional analysis of the BRCA1 promoter/5'-UTR in families from Upper Silesia, Poland
por: Pamuła, J, et al.
Publicado: (2005)

Copper transport system and response to ovarian cancer chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Pharmacogenetics of FAC chemotherapy side effects in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2015)

Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2016)

The putative oncogene, CRNDE, is a negative prognostic factor in ovarian cancer patients
por: Szafron, Lukasz Michal, et al.
Publicado: (2015)

Genetic 3′UTR variations and clinical factors significantly contribute to survival prediction and clinical response in breast cancer patients
por: Pamuła-Piłat, Jolanta, et al.
Publicado: (2020)

Genetic polymorphisms and ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Genetic polymorphisms, efficiency and toxicity of cancer chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2018)

Hereditary breast and ovarian cancer
por: Gronwald, Jacek, et al.
Publicado: (2008)

Folic acid and cancer risk in BRCA1 carriers
por: Durda, Katarzyna, et al.
Publicado: (2012)

Immunophenotypic predictive profiling of BRCA1-associated breast cancer
por: Domagala, Pawel, et al.
Publicado: (2010)

Meeting abstracts from the Annual Conference on Hereditary Cancers 2015: Szczecin, Poland. 24-25 September, 2015
por: Thompson, Ella R., et al.
Publicado: (2017)

The Relationship between Histological Composition and Metabolic Profile in Breast Tumors and Peritumoral Tissue Determined with (1)H HR-MAS NMR Spectroscopy
por: Skorupa, Agnieszka, et al.
Publicado: (2023)

Clinicopathological characteristics of breast cancer patients with NOD2 mutation according to age
por: Huszno, Joanna, et al.
Publicado: (2020)

Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinoma—Do They Exist?
por: Szpak-Ulczok, Sylwia, et al.
Publicado: (2020)

CDH1 gene mutations do not contribute in hereditary diffuse gastric cancer in Poland
por: Jakubowska, Anna, et al.
Publicado: (2010)

BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma
por: Rusinek, Dagmara, et al.
Publicado: (2015)

BRCA2 gene mutations in families with aggregations of breast and stomach cancers
por: Jakubowska, A, et al.
Publicado: (2002)

Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2017)

Corrigendum: Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2017)

Genetic testing for hereditary breast cancer in Poland: 1998–2022
por: Gronwald, Jacek, et al.
Publicado: (2023)

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor
por: Ogrodniczak, Alicja, et al.
Publicado: (2022)

Molecular differential diagnosis of follicular thyroid carcinoma and adenoma based on gene expression profiling by using formalin-fixed paraffin-embedded tissues
por: Pfeifer, Aleksandra, et al.
Publicado: (2013)

Fibronectin and Periostin as Prognostic Markers in Ovarian Cancer
por: Kujawa, Katarzyna Aleksandra, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3ufc8fhh4d6v854sd6bki2til3